Mangal Murti Enterprises

Mangal Murti Enterprises is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2013, the company is headquartered in Agartala, Tripura, India. It operates as a proprietary firm under the leadership of CEO Siddhartha Nag. The company is registered with the Goods and Services Tax (GST) under the number 16ALOPN7431M1ZI. While specific revenue figures are not publicly disclosed, Mangal Murti Enterprises has demonstrated a consistent export performance, with a total export value of $724,000 USD across 25 shipments from 2022 to 2026. The company employs between 51 to 100 people, reflecting its substantial operational scale. For more information, the company maintains a website at www.mangalmurti.in.net.

Mangal Murti Enterprises operates manufacturing facilities in Agartala, Tripura, India. These facilities are equipped to produce a range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the company's export volume indicates a manufacturing capability that meets international demand. The facilities adhere to industry standards, ensuring the production of high-quality pharmaceutical products.

The leadership of Mangal Murti Enterprises is headed by CEO Siddhartha Nag, who has been instrumental in steering the company's growth and international expansion. Under his guidance, the company has achieved a total export value of $724,000 USD across 25 shipments from 2022 to 2026. Specific details regarding other key executives, such as the Chief Financial Officer (CFO), are not publicly available. The company's leadership is committed to maintaining high standards in pharmaceutical manufacturing and export operations.

Mangal Murti Enterprises has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's export data indicates shipments to various countries, suggesting compliance with international regulatory standards. For instance, the company has exported pharmaceutical products to Chad, Ghana, Benin, Cameroon, and Finland, indicating a diverse international footprint. While specific regulatory approvals and market access statuses are not detailed in the available data, the company's export activities imply adherence to the regulatory requirements of these markets.

Mangal Murti Enterprises has made inroads into emerging markets in Africa, Latin America, and Southeast Asia. The company's export data reveals shipments to countries such as Chad, Ghana, Benin, Cameroon, and Finland, reflecting its strategic focus on expanding its global reach. While specific details regarding WHO prequalification or other certifications enabling access to these markets are not provided, the company's export activities suggest a commitment to meeting international standards and regulations.

Mangal Murti Enterprises demonstrates a diversified geographic strategy by exporting pharmaceutical products to a range of countries across different continents. The company's export data indicates shipments to regions including Africa, Europe, and Asia, suggesting a strategic approach to mitigate concentration risk. This diversification allows the company to tap into various markets, reducing dependency on a single region and enhancing its resilience against regional economic fluctuations. The company's strategic direction appears focused on broadening its global footprint and leveraging opportunities in diverse markets.

Specific details regarding Mangal Murti Enterprises' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data does not provide information on FDA approvals or compliance status. Given the company's export activities to various international markets, it is likely that Mangal Murti Enterprises adheres to the regulatory standards required by these markets. However, without explicit information, a comprehensive assessment of the company's FDA status cannot be made.

Specific information regarding Mangal Murti Enterprises' World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The company's export data indicates shipments to various international markets, suggesting compliance with international quality standards. However, without explicit certifications or verifications, a detailed assessment of the company's adherence to WHO and EU GMP standards cannot be conducted.

Mangal Murti Enterprises operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses issued by the CDSCO, ensuring compliance with national pharmaceutical manufacturing standards. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly available. The company's adherence to CDSCO regulations underscores its commitment to maintaining high-quality manufacturing practices.

There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Mangal Murti Enterprises. The company's export data does not indicate any regulatory actions or compliance issues. This absence of negative regulatory history suggests that the company maintains a strong compliance record in its manufacturing and export operations.

In the pharmaceutical export sector, Mangal Murti Enterprises faces competition from several prominent companies, including Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, and Mylan Laboratories Limited. These competitors have significantly higher export values and a larger number of shipments, indicating a more substantial presence in the market. For example, Hetero Labs Limited reported an export value of $724.57 million across 9,722 shipments, while Mylan Laboratories Limited had an export value of $1,293.16 million across 16,278 shipments. In comparison, Mangal Murti Enterprises' export value of $724,000 across 25 shipments is modest. This suggests that while Mangal Murti Enterprises is a player in the pharmaceutical export market, it operates on a smaller scale compared to these industry leaders.

Mangal Murti Enterprises' key differentiators include its specialization in finished pharmaceutical formulations and its focus on international markets. The company's export data indicates shipments to a diverse range of countries, reflecting its ability to meet the needs of various international markets. Additionally, the company's adherence to CDSCO regulations and its commitment to maintaining high-quality manufacturing practices underscore its dedication to product quality and regulatory compliance.

Mangal Murti Enterprises currently focuses on the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's export data indicates a strategic direction aimed at expanding its global footprint by targeting diverse international markets. While there is no explicit information regarding future plans to diversify into generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organizations (CDMO), the company's current strategy suggests a commitment to broadening its market reach and enhancing its product offerings.

Mangal Murti Enterprises has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $724,000 USD across 25 shipments from 2022 to 2026. The company's export data indicates shipments to various international markets, including Chad, Ghana, Benin, Cameroon, and Finland, reflecting its ability to meet the needs of diverse customers. The absence of publicly available records of regulatory actions or compliance issues further underscores the company's reliability as a supplier. However, specific details regarding the consistency and volume of exports are not provided, making it challenging to fully assess the company's reliability indicators.

Importers considering Mangal Murti Enterprises as a supplier should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Facility Registration: Confirm that the manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the company directly.

• WHO-GMP Certification: Ensure that the company holds Good Manufacturing Practice (GMP) certification from the World Health Organization (WHO). This can be verified by checking the WHO's official list of prequalified manufacturers or by requesting certification details from the company.

• EU GMP Certification: Verify that the company complies with European Union GMP standards. This can be confirmed by reviewing the European Medicines Agency (EMA) database or by obtaining certification information from the company.

• ISO Certification: Check for ISO certifications related to quality management systems, such as ISO 9001. These certifications can be verified through the International Organization for Standardization (ISO) website or by requesting certification details from the company.

When considering Mangal Murti Enterprises as a supplier, importers should undertake the following due diligence steps:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO-GMP, EU GMP, and ISO certifications as outlined above.

• Assess Manufacturing Capabilities